ライフサイエンスコーパス: advanced breast cancer

1 patients with aromatase inhibitor-resistant advanced breast cancer.

2 e in women with BRCA1 or BRCA2 mutations and advanced breast cancer.

3 occurrence in the majority of patients with advanced breast cancer.

4 ptake and patterns of aggressive behavior in advanced breast cancer.

5 outcome for women with both early-stage and advanced breast cancer.

6 al growth factor receptor 2 (HER2) -positive advanced breast cancer.

7 ctomy for the treatment of early and locally advanced breast cancer.

8 chemotherapy on ECD levels, in patients with advanced breast cancer.

9 xel (GD) with capecitabine-docetaxel (CD) in advanced breast cancer.

10 combination in patients with ErbB2-positive advanced breast cancer.

11 n a phase II clinical trial in patients with advanced breast cancer.

12 axel (GT) versus paclitaxel in patients with advanced breast cancer.

13 apy in patients with inflammatory or locally advanced breast cancer.

14 vant therapy for HER2-overexpressing locally advanced breast cancer.

15 apeutic approach to treat inoperable locally advanced breast cancer.

16 s for patients with locally and systemically advanced breast cancer.

17 hemotherapy in women with primary or locally advanced breast cancer.

18 epilone in women with metastatic and locally advanced breast cancer.

19 to doxorubicin-based chemotherapy in locally advanced breast cancer.

20 ion should be evaluated for the treatment of advanced breast cancer.

21 mal growth factor receptor 2 (HER2)-positive advanced breast cancer.

22 nducted a phase II study in 76 patients with advanced breast cancer.

23 nd are more likely to receive a diagnosis of advanced breast cancer.

24 tment of anthracycline- and taxane-resistant advanced breast cancer.

25 ith hormone receptor-positive, HER2-positive advanced breast cancer.

26 owth factor receptor 2 (HER2) overexpressing advanced breast cancer.

27 and/or poor-performance status patients with advanced breast cancer.

28 DK6 is now part of the standard treatment in advanced breast cancer.

29 pically distinct from other forms of locally advanced breast cancer.

30 imal schedules of taxanes in early-stage and advanced breast cancer.

31 emotherapy response in patients with locally advanced breast cancer.

32 herapy compared with GM-CSF in patients with advanced breast cancer.

33 e, hormone receptor-positive, ERBB2-negative advanced breast cancer.

34 trogen receptor (ER)-positive, HER2-negative advanced breast cancer.

35 of neoadjuvant treatment outcomes in locally advanced breast cancer.

36 t of AR-positive, ER-positive, HER2-negative advanced breast cancer.

37 and remains a critical challenge in treating advanced breast cancer.

38 atabase, including for metastatic or locally advanced breast cancer.

39 in patients with HR-positive, HER2-negative advanced breast cancer.

40 T cells using an orthotopic model of locally advanced breast cancer.

41 mal growth factor receptor 2 (HER2)-negative advanced breast cancer.

42 romising strategy for treating patients with advanced breast cancer.

43 endent kinase 4 and 6 inhibitor approved for advanced breast cancer.

44 to impact and guide management decisions for advanced breast cancer.

45 al growth factor receptor 2-negative (HER2-) advanced breast cancer.

46 e, hormone receptor-positive, ERBB2-negative advanced breast cancer.

47 ential agent for advanced bladder cancer and advanced breast cancer.

48 th hormone receptor-positive, HER2-negative, advanced breast cancer.

49 potential combinatorial treatment options in advanced breast cancer.

50 th hormone receptor-positive, HER2-negative, advanced breast cancer.

51 hibitor-resistant ER-positive, HER2-negative advanced breast cancer.

52 oestrogen receptor-positive, HER2-negative, advanced breast cancer.

53 patients with PD-L1-positive, HER2-positive advanced breast cancer.

54 hormone receptor-positive and HER2-negative advanced breast cancer.

55 ation chemotherapy is commonly used to treat advanced breast cancer.

56 eviously treated patients with HER2-positive advanced breast cancer.

57 epidermal growth factor receptor 2-negative advanced breast cancer.

58 by prior aromatase inhibitor (AI) therapy in advanced breast cancer.

59 49 eligible randomised controlled trials of advanced breast cancer.

60 ndard therapy for estrogen receptor-positive advanced breast cancer.

61 cian's choice plus trastuzumab in women with advanced breast cancer.

62 Bone metastases are common in patients with advanced breast cancer.

63 of estrogen receptor-positive, HER2-negative advanced breast cancer.

64 with HER2-negative/hormone receptor-positive advanced breast cancer.

65 choice in patients with heavily pre-treated advanced breast cancer.

66 ne treatment for patients with HER2-positive advanced breast cancer.

67 ients with germline BRCA mutation-associated advanced breast cancer.

68 metastases among patients with HER2-positive advanced breast cancer.

69 crine therapy for patients with HER-positive advanced breast cancer.

70 ug Administration (FDA) for the treatment of advanced breast cancer.

71 istant and taxane-pretreated, HER2-positive, advanced breast cancer.

72 first-line therapy in patients with AI-naive advanced breast cancer.

73 rexpressed in breast cancer, particularly in advanced breast cancer.

74 improved PFS in patients with HER2-negative advanced breast cancer.

75 mechanism of metastasis and hypercalcemia in advanced breast cancers.

76 a potential precision treatment strategy for advanced breast cancers.

77 n initial staging of inflammatory or locally advanced breast cancer?

78 In a previous trial in women with locally advanced breast cancer, 3 months of high-dose epirubicin

79 ars (range, 30 to 90 years); 32% had locally advanced breast cancer, 42% had been diagnosed with brea

80 th high versus low or average risk of 6-year advanced breast cancer (5.5 [95% CI: 3.5, 8.6] vs 1.3 [9

81 ugh trastuzumab is approved for treatment of advanced breast cancer, a number of concerns exist with

82 with these Abs are approved for treatment of advanced breast cancer, a number of concerns exist.

83 mal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) demonstrated significant PF

84 The genomics of advanced breast cancer (ABC) has been described through

85 patients with hormone receptor (HR)-positive advanced breast cancer (ABC) resulted in statistically s

86 al growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with disease progression on

87 versus letrozole (LET) in receptor-positive advanced breast cancer (ABC).

88 h factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC).

89 rowth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).

90 epidermal growth factor receptor 2-negative advanced breast cancer (ABC).

91 al growth factor receptor-2-negative (HER2-) advanced breast cancers (ABCs) and is associated with po

92 metastases among patients with HER2-positive advanced breast cancer.Additional information is availab

93 II study documents a role for gemcitabine in advanced breast cancer after anthracycline-based adjuvan

94 acy of this technique for patients with more advanced breast cancer after neoadjuvant chemotherapy.

95 ed, hormone receptor-positive, HER2-negative advanced breast cancer, after progression on a CDK4/6 in

96 ssociated with a significantly lower risk of advanced breast cancer among the 3.6% of women with extr

97 ctometry was associated with reduced risk of advanced breast cancer among women with light constituti

98 hesis that sunlight exposure reduces risk of advanced breast cancer among women with light skin pigme

99 progression, in patients with HER2-negative advanced breast cancer and a germline BRCA1 or BRCA2 mut

100 In women with advanced breast cancer and acquired resistance to aromat

101 -DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to

102 llness were more likely to be diagnosed with advanced breast cancer and aggressive tumor characterist

103 ed >=18 years) with histologically confirmed advanced breast cancer and an Eastern Cooperative Oncolo

104 th hormone-receptor-positive, HER2-negative, advanced breast cancer and an Eastern Cooperative Oncolo

105 Women aged 18 years or older with advanced breast cancer and baseline clinical anxiety wer

106 ow that CBD can be used safely in women with advanced breast cancer and clinical anxiety.

107 One hundred ninety-one patients with locally advanced breast cancer and cytologically documented ALN

108 s), derived from blood samples of women with advanced breast cancer and directly inoculated into the

109 States are more likely to be diagnosed with advanced breast cancer and have a higher risk of mortali

110 e occurred in all five patients with locally advanced breast cancer and in eight of 20 patients (40%;

111 e standard of care for patients with locally advanced breast cancer and is being evaluated in patient

112 hly active in women with HER2-overexpressing advanced breast cancer and is well tolerated.

113 ly pretreated, endocrine-resistant HR+/HER2- advanced breast cancer and limited treatment options.

114 guidelines, staging of patients with locally advanced breast cancer and local-regional recurrent brea

115 by number of previous systemic therapies for advanced breast cancer and measurable versus non-measura

116 usion, D1R overexpression is associated with advanced breast cancer and poor prognosis.

117 This AMPK-PDHc axis is activated in advanced breast cancer and predicts poor metastasis-free

118 with hormone receptor-positive/HER2-negative advanced breast cancer and progression during/after arom

119 e recommendations to encompass patients with advanced breast cancer and rare tumours such as gastroin

120 d to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing

121 cause mortality, as well as the incidence of advanced breast cancer and treatment-related morbidity;

122 a suggest that the cMethDNA assay can detect advanced breast cancer, and monitor tumor burden and tre

123 orld region, number of previous regimens for advanced breast cancer, and presence of visceral disease

124 tients with previously treated HER2-positive advanced breast cancer, and validate HER2 as a therapeut

125 BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of loc

126 that 14-3-3 zeta is overexpressed in >40% of advanced breast cancers, and this overexpression predict

127 differences in approach to and management of advanced breast cancer; and (4) discuss treatment in ter

128 ntrol study found that individuals with more advanced breast cancer at diagnosis were more likely to

129 nonwhite ethnicity, be obese, and have more advanced breast cancer at diagnosis.

130 ten patients with biopsy-confirmed, locally advanced breast cancer at the pre-treatment timepoint.

131 routinely screened women, the proportion of advanced breast cancers attributed to biennial vs annual

132 umab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free

133 formed outcomes in patients with ER+ /HER2 - advanced breast cancer (BC).

134 ancer on the incidence of and progression to advanced breast cancer, breast cancer morbidity, and bre

135 (FDG), is applied for whole-body staging in advanced breast cancer but has limited accuracy in evalu

136 ted the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression.

137 k factors that explain a large proportion of advanced breast cancers by race and ethnicity are unknow

138 Resequencing in a multiethnic panel of 95 advanced breast cancer cases revealed no common missense

139 he EGFR is common in many cancers, including advanced breast cancer, characterization of EGF-induced

140 ain, Saudi Arabia, Oman, Qatar, and Kuwait), advanced breast cancer, colorectal cancer, leukaemia, th

141 niluracil has high activity in patients with advanced breast cancer comparable with the most active c

142 of the physician's choice for patients with advanced breast cancer demonstrated a significant improv

143 s) screening mammograms associated with 1815 advanced breast cancers diagnosed within 2 years of scre

144 To reduce the number of advanced breast cancer diagnoses, primary prevention sho

145 of ramucirumab to docetaxel in HER2-negative advanced breast cancer did not meaningfully improve impo

146 epidermal growth factor receptor 2-negative advanced breast cancer, each intrinsic subtype exhibited

147 particle emitter, has potential for treating advanced breast cancer, especially human epidermal growt

148 recommended for patients with HER2-positive advanced breast cancer, except for those with clinical c

149 ng everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/progressi

150 ted from patients with metastatic or locally advanced breast cancer express high levels of the adipon

151 trogen therapy was the standard treatment of advanced breast cancer for three decades until the disco

152 Advanced breast cancers frequently metastasize to bone,

153 ed DCE-MR images from 132 women with locally advanced breast cancer from the I-SPY1 trial to evaluate

154 iscriminating patients with stage II or more advanced breast cancers from healthy females had an area

155 R61 transcripts in tumors from patients with advanced breast cancer, further ratifying the clinical r

156 The LABC (locally advanced breast cancer) group included 17 patients with

157 PK pathway contributes to the maintenance of advanced breast cancers harboring Pten loss.

158 ase II and III trials of hormonal therapy in advanced breast cancer have examined the role of exemest

159 iscovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carc

160 the subclonal diversification of pre-treated advanced breast cancer, identifying distinct mutational

161 more high-risk alleles increases the risk of advanced breast cancer in a dose-response fashion.

162 49 tissue samples from patients with locally advanced breast cancer in a prospective study.

163 dered for use as an alternative treatment of advanced breast cancer in postmenopausal women after tre

164 graphy to characterize HA in mouse models of advanced breast cancer in relevant skeletal locations.

165 ptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are avai

166 ptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are avai

167 d limitations of serum ECD in both early and advanced breast cancer in the following clinical context

168 d demonstrated activity in patients with ER+ advanced breast cancer in this signal-finding phase II s

169 We found an increased risk of advanced breast cancer in women carrying an A2 allele.

170 EER) database suggests that the incidence of advanced breast cancer in young women is increasing.

171 esults with the intervention; no longer-term advanced breast cancer incidence or morbidity and mortal

172 Approvals for oestrogen receptor-positive advanced breast cancer include the PI3K inhibitor alpeli

173 tumorsphere formation in multiple models of advanced breast cancer including tamoxifen (TamR) and pa

174 buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the P

175 e other hand, Hsf1 expression increases with advanced breast cancer, indicating that there is an addi

176 distant metastases) in patients with locally advanced breast cancer initially staged at fluorine 18 (

177 Much of the morbidity of advanced breast cancer is a consequence of this process.

178 mal growth factor receptor 2 (HER2)-negative advanced breast cancer is a rapidly evolving field owing

179 in as first-line chemotherapy for women with advanced breast cancer is an active regimen.

180 ave recently reported that increased risk of advanced breast cancer is associated with a common allel

181 ing whether these refugees present with more-advanced breast cancer is crucial for guiding resource a

182 of tamoxifen in the sequential strategy for advanced breast cancer is less well studied.

183 s, a clinical trial in patients with locally advanced breast cancer is planned.

184 Improvements in the treatment of locally advanced breast cancer (LABC) are needed.

185 Locally advanced breast cancer (LABC) is commonly treated with n

186 rd-of-care imaging (SOC) for staging locally advanced breast cancer (LABC) or evaluating suspected re

187 ating patients with chemorefractory, locally advanced breast cancer (LABC) or metastatic TNBC.

188 The prognosis of patients with locally advanced breast cancer (LABC) remains poor.

189 haracterize the biologic response of locally advanced breast cancer (LABC) to chemotherapy using (15)

190 Patients with locally advanced breast cancer (LABC) typically undergo staging

191 inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to

192 he conventional primary treatment in locally advanced breast cancer (LABC).

193 prospectively to a second set of 20 locally advanced breast cancer lesions not included in the initi

194 opausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatme

195 An advanced breast cancer model was established by inoculat

196 usters versus single CTCs from patients with advanced breast cancer (mostly female).

197 ader, in postmenopausal women with ER+/HER2- advanced breast cancer (NCT03284957), who were mostly he

198 Patients with advanced breast cancer often fail to respond to treatmen

199 Brain metastasis of advanced breast cancer often results in deleterious cons

200 treatment of naive hormone receptor-positive advanced breast cancer on the basis of an improvement in

201 Patients with HER2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/k

202 Patients with locally advanced breast cancer or MBC were treated with the arom

203 at least one previous line of treatment for advanced breast cancer or relapsed within 12 months of n

204 95% CI (confidence interval), 0.65-1.12] or advanced breast cancer (OR, 0.84; 95% CI, 0.54-1.32).

205 e first demonstrate that a majority of large advanced breast cancers overexpress translation regulato

206 effective in the treatment of patients with advanced breast cancer overexpressing or amplifying HER2

207 provides a promising reagent for inhibiting advanced breast cancer pathogenesis.

208 nse to Cyclin-dependent kinase inhibitors in advanced breast cancer patients (p < 0.05), identifying

209 Our data show that advanced breast cancer patients have an increased propor

210 es, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n

211 Advanced breast cancer patients were treated with ixabep

212 time to aromatase inhibitor (AI) therapy in advanced breast cancer patients, and found that circCNOT

213 For 20 newly diagnosed, untreated, locally advanced breast cancer patients, both the maximum SUV an

214 al metastases, the leading cause of death in advanced breast cancer patients, depend on tumor cell in

215 ent of resistance to aromatase inhibitors in advanced breast cancer patients.

216 improve clinical outcomes for both early and advanced breast cancer patients.

217 is may help eradicate this deadly feature in advanced breast cancer patients.

218 NK cell functions are profoundly altered in advanced breast cancer patients.

219 The safety profile was consistent with an advanced breast cancer population receiving systemic the

220 ears) with centrally confirmed HER2-positive advanced breast cancer previously treated with both tras

221 l in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroi

222 ntrally confirmed, measurable, HER2-positive advanced breast cancer previously treated with trastuzum

223 capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzum

224 ized trial, patients with metastatic/locally advanced breast cancer previously untreated for advanced

225 ithin 12 months of screening mammography and advanced breast cancer (prognostic pathologic stage II o

226 Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aro

227 are needed to evaluate interval invasive and advanced breast cancer rates, intermediary outcomes rela

228 Endocrine therapy resistance in advanced breast cancer remains a significant clinical pr

229 stance, and its ultimate place in therapy of advanced breast cancer remains to be determined.

230 Patients with locally advanced breast cancer require multimodality treatment c

231 In patients with advanced breast cancer responsive to cytotoxic chemother

232 ients with high versus low or average 6-year advanced breast cancer risk (37.0 [95% CI: 28.2, 48.4] v

233 C risk prediction models of estimated 6-year advanced breast cancer risk and 5-year invasive breast c

234 e a biomarker for the onset of ovulation and advanced breast cancer risk.

235 Sixteen women with biopsy-confirmed locally advanced breast cancer scheduled to undergo doxorubicin-

236 SPECT/CT imaging in patients with advanced breast cancer showed focal uptake of (131)I-GMI

237 in patients with ER-positive, HER2-negative advanced breast cancer, showing that AR activation can r

238 se did not appear to have translated to more advanced breast cancer stages at diagnosis or decreases

239 The genetic complexity observed in advanced breast cancer suggests that such treatments sho

240 docetaxel versus paclitaxel in patients with advanced breast cancer that had progressed after an anth

241 ed to test this combination in HER2-positive advanced breast cancer that had progressed after previou

242 ment option for postmenopausal patients with advanced breast cancer that has become refractory to sta

243 pecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatme

244 or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone rece

245 e sought to study in detail these aspects of advanced breast cancers that have resulted in lethal dis

246 Hypoxia is a common feature of locally advanced breast cancers that is associated with increase

247 mic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free

248 epidermal growth factor receptor 2-negative advanced breast cancer, the STIC CTC trial established t

249 ghly expressed in both cancer cell lines and advanced breast cancer tissues, and the levels of TRIM28

250 MRI data to predict the response of locally advanced breast cancer to neoadjuvant therapy in a commu

251 epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy an

252 n hematopoietic recovery in 88 patients with advanced breast cancer treated with high-dose chemothera

253 xtracellular domain (sHER2) in patients with advanced breast cancer treated with lapatinib using data

254 epidermal growth factor receptor-2 negative advanced breast cancer treated with ribociclib plus ET o

255 outcomes for a small number of patients with advanced breast cancer treated with weekly infusions of

256 line DCE-MRI scans of 156 women with locally advanced breast cancer, treated with neoadjuvant chemoth

257 astrozole Compared in Hormonal Therapy Naive Advanced Breast Cancer) trial.

258 ograms/kg/d for 5 or 7 days in 38 women with advanced breast cancer undergoing high-dose chemotherapy

259 Thirty-nine patients with locally advanced breast cancer underwent (18)F-FDG PET before an

260 with estrogen receptor (ER)-positive locally advanced breast cancer was investigated by analyzing tum

261 Survival in advanced breast cancer was not affected by group therapy

262 of paclitaxel and cisplatin in patients with advanced breast cancer was performed to determine the ob

263 Advanced breast cancer was reduced for women aged 50 yea

264 rmed BRCA1 or BRCA2 mutations and recurrent, advanced breast cancer were assigned to two sequential c

265 nts with anthracycline- and taxane-resistant advanced breast cancer were enrolled onto this open-labe

266 ts that are now outdated, and definitions of advanced breast cancer were heterogeneous.

267 ber 1988 and January 1991, 534 patients with advanced breast cancer were randomized to two multicente

268 with HER2-positive MBC or recurrent locally advanced breast cancer were randomly assigned to trastuz

269 y-one patients with inflammatory and locally advanced breast cancer were treated with bevacizumab for

270 ohorts of three patients with ErbB2-positive advanced breast cancer were treated with escalating dose

271 Patients with inflammatory or locally advanced breast cancer were treated with one cycle of be

272 with advanced prostate cancer, myeloma, and advanced breast cancer were used for model testing, and

273 All locally advanced breast cancers were (18)F-fluciclovine-avid.

274 ore than one in 10 participants with locally advanced breast cancer, which was more than 2.5 times mo

275 oprotective agent when used in patients with advanced breast cancer who continue to receive doxorubic

276 e status 0-2) with progressive HER2-positive advanced breast cancer who had received two or more HER2

277 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression

278 ith hormone receptor-positive, HER2-negative advanced breast cancer who had relapse or disease progre

279 new standard for patients with HER2-positive advanced breast cancer who have previously received tras

280 n the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxife

281 wo FDG PET scans in 12 patients with locally advanced breast cancer who received G-CSF treatment were

282 Forty-one patients with advanced breast cancer who were either over the age of 6

283 t in patients with hormone receptor-positive advanced breast cancer who were not given dexamethasone

284 buparlisib plus fulvestrant in patients with advanced breast cancer who were pretreated with endocrin

285 Patients with advanced breast cancer who were treated with HDC without

286 andomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated

287 One hundred two women with advanced breast cancer, who were offered palliative chem

288 eatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamox

289 rative chemotherapy in patients with locally advanced breast cancer with better sensitivity for prima

290 Advanced breast cancer with distant organ metastases is

291 on cost-effectiveness of liver resection for advanced breast cancer with liver metastasis are lacking

292 erphase, and have low or no efficacy against advanced breast cancer with mutant or deficient p53.

293 th hormone receptor-positive, ERBB2-negative advanced breast cancer with no prior therapy in the meta

294 th hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, foll

295 had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanc

296 r older, with locally assessed HER2-positive advanced breast cancer, with Eastern Cooperative Oncolog

297 ated into major advances in the treatment of advanced breast cancer, with several targeted therapies

298 ved previous trastuzumab or chemotherapy for advanced breast cancer within 12 months of randomisation

299 nesis is an established prognostic factor in advanced breast cancer, yet response to antiangiogenic t